Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
3223460
Reference Type
Journal Article
Title
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development
Author(s)
Tibbitts, Jay; Canter, D; Graff, R; Smith, A; Khawli, LA
Year
2016
Is Peer Reviewed?
1
Journal
mAbs
ISSN:
1942-0862
Volume
8
Issue
2
Page Numbers
229-245
DOI
10.1080/19420862.2015.1115937
Web of Science Id
WOS:000371345100004
Abstract
Protein therapeutics represent a diverse array of biologics including antibodies, fusion proteins, and therapeutic replacement enzymes. Since their inception, they have revolutionized the treatment of a wide range of diseases including respiratory, vascular, autoimmune, inflammatory, infectious, and neurodegenerative diseases, as well as cancer. While in vivo pharmacokinetic, pharmacodynamic, and efficacy studies are routinely carried out for protein therapeutics, studies that identify key factors governing their absorption, distribution, metabolism, and excretion (ADME) properties have not been fully investigated. Thorough characterization and in-depth study of their ADME properties are critical in order to support drug discovery and development processes for the production of safer and more effective biotherapeutics. In this review, we discuss the main factors affecting the ADME characteristics of these large macromolecular therapies. We also give an overview of the current tools, technologies, and approaches available to investigate key factors that influence the ADME of recombinant biotherapeutic drugs, and demonstrate how ADME studies will facilitate their future development.
Keywords
labeling; subcutaneous bioavailability; antibody-drug conjugate (ADC); imaging; monoclonal antibody (mAb); metabolism; biologics; pharmacokinetics; Absorption; neonatal Fc receptor (FcRn); excretion; distribution; biotherapeutics
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity